Evaluation of Antibiotic Therapy for Eradication of “Candidatus Helicobacter heilmannii”

ABSTRACT Triple-agent therapy with lansoprazole (15 mg/kg)-clarithromycin (50 mg/kg)-amoxicillin (50 mg/kg) twice daily for 7 days fully cleared “Candidatus Helicobacter heilmannii” from infected mouse stomachs. Moreover, gastric mucosa-associated lymphoid tissue lymphoma-like lesions in the stomach nearly disappeared in the treated mice 4 months after the therapy.

[1]  T. Hibi,et al.  “Candidatus Helicobacter heilmannii” from a Cynomolgus Monkey Induces Gastric Mucosa-Associated Lymphoid Tissue Lymphomas in C57BL/6 Mice , 2006, Infection and Immunity.

[2]  F. Haesebrouck,et al.  Evaluation of Antibiotic Treatment against “Candidatus Helicobacter suis” in a Mouse Model , 2005, Antimicrobial Agents and Chemotherapy.

[3]  K. Sano,et al.  Helicobacter heilmannii infection: Clinical, endoscopic and histopathological features in Japanese patients , 2005, Pathology international.

[4]  J. Fox,et al.  The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases , 2002, Gut.

[5]  S. Okabe,et al.  Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication , 2001, Journal of Physiology-Paris.

[6]  David B. Schauer,et al.  Emergence of Diverse HelicobacterSpecies in the Pathogenesis of Gastric and Enterohepatic Diseases , 2001, Clinical Microbiology Reviews.

[7]  M. Stolte,et al.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. , 2000, Gastroenterology.

[8]  L. D'Alteroche,et al.  Lymphome gastrique de bas grade du MALT et Helicobacter heilmannii (Gastrospirillum hominis). , 1998 .

[9]  C. Mcnulty,et al.  New spiral bacterium in gastric mucosa. , 1989, Journal of clinical pathology.

[10]  C. Copie-Bergman,et al.  [Low-grade gastric MALT lymphoma and helicobacter heilmannii (Gastrospirillum hominis]. , 1998, Gastroenterologie clinique et biologique.